Zobrazeno 1 - 10
of 132
pro vyhledávání: '"F. Poullenot"'
Autor:
P. Rivière, A. Le Chevillier, A. Rullier, M. Marty, E. Schurr, B. Lapuyade, B. Célerier, B. Fernandez, T. Bessissow, X. Treton, M. Uzzan, F. Poullenot, A. Berger, F. Zerbib, D. Laharie
Publikováno v:
Digestive and Liver Disease.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6d8a9c9f52ca94ae8cb9cbf1226bc385
https://doi.org/10.1016/j.dld.2023.05.004
https://doi.org/10.1016/j.dld.2023.05.004
Publikováno v:
Nutrition Clinique et Métabolisme. 37:e97
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b672d280f586a63b12908e94f9fc5ec
https://doi.org/10.1016/j.nupar.2023.03.180
https://doi.org/10.1016/j.nupar.2023.03.180
Autor:
G Le Cosquer, C Gilletta, A Amiot, P Rivière, M Nachury, C Rouillon, Y Bouhnik, V Abitbol, S Nancey, M Fumery, G Savoye, A Biron, L Picon, L Peyrin-Biroulet, M Vidon, C Reenaers, M Simon, B Caron, M Serrero, R Altwegg, A Benezech, F Goutorbe, J F Rahier, L Beaugerie, A L Pelletier, L Caillo, D Laharie, F Poullenot
Publikováno v:
Journal of Crohn's and Colitis
Journal of Crohn's and Colitis, 2023, 17 (Supplement 1), pp.i572-i572. ⟨10.1093/ecco-jcc/jjac190.0573⟩
Journal of Crohn's and Colitis, 2023, 17 (Supplement 1), pp.i572-i572. ⟨10.1093/ecco-jcc/jjac190.0573⟩
Background Breast cancer is the most common malignancy observed in patients with inflammatory bowel diseases (IBD) unrelated to the disease or its treatment (Poullenot F et al. JCC 2022). The main aim of our study was to assess the risk of incident c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a58a414d1b5237c1930c6c7670ed2eb
https://doi.org/10.1093/ecco-jcc/jjac190.0573
https://doi.org/10.1093/ecco-jcc/jjac190.0573
Autor:
F Poullenot, A Amiot, M Nachury, S Viennot, R Altwegg, Y Bouhnik, V Abitbol, S Nancey, L Vuitton, L Peyrin-Biroulet, A Biron, M Fumery, L Picon, M Vidon, C Reenaers, M Serrero, G Savoye, L Beaugerie, P Rivière, D Laharie
Publikováno v:
Journal of Crohn's and Colitis
Journal of Crohn's and Colitis, 2022, 16 (10), pp.1523-1530. ⟨10.1093/ecco-jcc/jjac061⟩
Journal of Crohn's and Colitis, 2022, 16 (10), pp.1523-1530. ⟨10.1093/ecco-jcc/jjac061⟩
Introduction Knowledge about the cancer risk when initiating a biologic in inflammatory bowel disease [IBD] patients with prior malignancy remains scarce, especially for vedolizumab. Our aim was to evaluate the rate of incident cancer in a cohort of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17f22cc6a4e0b0eee459214fd8327e50
https://pubmed.ncbi.nlm.nih.gov/35512337
https://pubmed.ncbi.nlm.nih.gov/35512337
Autor:
F. Joly, D. Quilliot, C. Chambrier, S. Schneider, G. Fotsing, F. Poullenot, S. Layec, N. Flori, R. Thibault, E. Fontaine, E. Ressiot, V. Campana, N. Schmidely, D. Seguy
Publikováno v:
Nutrition Clinique et Métabolisme. 36:S2-S3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3eab877d987e81f39fdc253c8bfb9af7
https://doi.org/10.1016/j.nupar.2021.12.004
https://doi.org/10.1016/j.nupar.2021.12.004
Autor:
F Poullenot, A Amiot, M Nachury, S Viennot, R Altwegg, Y Bouhnik, V Abitbol, S Nancey, L Vuitton, L Peyrin-Biroulet, A Biron, M Fumery, L Picon, M Vidon, C Reenaers, M Serrero, G Savoye, L Beaugerie, P Rivière, D Laharie
Publikováno v:
Journal of Crohn's and Colitis. 16:i362-i363
Background Knowledge about the cancer risk when initiating a biologic in Inflammatory Bowel Disease (IBD) patients with prior malignancy remains scarce especially for vedolizumab. Our aim was to evaluate the rate of incident cancer in a cohort of IBD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::47bf39e32332b9d906e104e83d7416d9
https://doi.org/10.1093/ecco-jcc/jjab232.477
https://doi.org/10.1093/ecco-jcc/jjab232.477
Autor:
J. Castinel, G. Pellet, F. Zerbib, D. Laharie, C. Silvain, E. Wilsius, L. Kerlogot, P. Rivière, F. Poullenot
Publikováno v:
Nutrition Clinique et Métabolisme. 36:S11
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4ed7698823abe845081f3a20ed544187
https://doi.org/10.1016/j.nupar.2021.12.020
https://doi.org/10.1016/j.nupar.2021.12.020
Autor:
G Le Cosquer, L Capirchio, P Rivière, N de Suray, F Poullenot, B De Vroey, A Berger, M A Denis, F Zerbib, R Bachmann, C Remue, B Celerier, D Leonard, Q Denost, A Kartheuser, D Laharie, O Dewit
Publikováno v:
Journal of Crohn's and Colitis. 16:i444-i444
Background The management of ulcerative colitis (UC) has been improved due to progresses in medical and surgical practices during the past twenty years. Yet the impact of new therapies on the evolution of the three colectomy’s indications in UC (se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3932fdddd90e25442d839bb9c98c413f
https://doi.org/10.1093/ecco-jcc/jjab232.599
https://doi.org/10.1093/ecco-jcc/jjab232.599
Autor:
P Riviere, C Kanters, A Ni, G Pellet, M Hupe, N Aboulhamid, F Poullenot, A Bitton, F Zerbib, P Lakatos, W Afif, D Laharie, T Bessissow
Publikováno v:
Journal of Crohn's and Colitis. 16:i479-i479
Background Real-life data on the efficacy of ustekinumab as first-line therapy for the treatment of moderate to severe Crohn’s disease (CD) is lacking. The objective of this study was to compare the clinical remission rate at 3 months of patients t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa9828dbbac87dc6b0c5db00a48ed4e0
https://doi.org/10.1093/ecco-jcc/jjab232.651
https://doi.org/10.1093/ecco-jcc/jjab232.651
Autor:
X. Treton, F. Poullenot
Publikováno v:
Côlon & Rectum. 12:207-210
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f6731d3aaf2c3e8b92f094755cbdee21
https://doi.org/10.3166/cer-2018-0040
https://doi.org/10.3166/cer-2018-0040